Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

CCR5 antagonist for enhancing immune reconstitution and treating opportunistic infection in HIV patients

A technology of immune reconstitution and antagonist, applied in the field of immune reconstitution, can solve problems such as accelerating AIDS

Inactive Publication Date: 2009-06-24
PFIZER PRODS ETAT DE CONNECTICUT
View PDF27 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

This in turn may accelerate the onset of AIDS and HIV-related opportunistic symptoms

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0140] The first cohort of treatment-experienced HIV-1 patients infected with CXCR4-using viral populations with optimized background therapy (OBT) was selected according to the following method with OBT + maraviroc once daily and OBT + daily The groups of the two Maravirocs were compared individually.

[0141] selection criteria

[0142] Patients enrolled in the trial :

[0143] (a) over the age of 16;

[0144] (b) Infection by a non-R5-tropic virus population (a CXCR4-using virus population) (when passed through Monogram Bioscience Phenosense TM When measured by assay (WO 02 / -99383; US5837464); or with an indeterminate tropism phenotype;

[0145] (c) have been on a stable antiviral regimen for at least 4 weeks before randomization:

[0146] (d) HIV-1 RNA count of at least 5,000 copies / mL (when measured by Roche Amplicor HIV-1monitor (version 1.5));

[0147] (e)(i) have at least three months of prior antiretroviral experience with at least one agent from four antiret...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to the use of a CCR5 antagonist in an HIV infected patient to enhance their immune reconstitution and so treat to HIV related opportunistic conditions resulting from the immunocompromised state of the HIV patient. The invention also allows treatment with a CCR5 antagonist of patients having a CXCR4 using viral population since such patients will also benefit from an increase in their CD4 and / or CD8 cell count.

Description

field of invention [0001] The present invention relates to the role of a CCR5 modulator, in particular an antagonist, in improving the efficacy of HIV (e.g. HIV-1)-infected patients with genetically related retroviral infection and resulting acquired immunodeficiency syndrome (AIDS). Use in immune reconstitution. The invention further includes the use of combinations comprising CCR5 antagonists in the treatment of HIV and AIDS patients. Background of the invention [0002] The name "chemokine" is " trend sex cells hormone ( chem tacticalcyto kines )". Chemotactic hormones include a large family of proteins that share important structural features and have the ability to attract leukocytes. As leukocyte chemokines, chemokines are indispensable in attracting leukocytes to different tissues of the body. role, this attraction is a necessary process for inflammation and the body's response to infection. Since chemokines and their receptors are important for the pathophysi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/439
CPCA61K31/439A61P31/06A61P31/10A61P31/18A61P33/02A61P37/00A61P37/02A61P37/04A61P43/00Y02A50/30
Inventor 霍华德·B·迈耶
Owner PFIZER PRODS ETAT DE CONNECTICUT
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com